For only the fourth time since World War II, the U.S. midterm election flipped control of both the House and the Senate. (The ...

A pair of popular modalities stands at the back-end-loaded, potential $7 billion-plus deal inked by Boehringer Ingelheim GmbH ...

China’s clinical trial advantage is beginning to reshape more than the development of Chinese drugs. Faster recruitment, lower costs and growing scientific capabilities are raising a broader question: ...

Med-tech financings across all categories totaled $3.29 billion in the third quarter (Q3) of 2026, down 14.5% from $3.86 billion in Q2 and 61% from $8.54 billion in Q1, marking the lowest quarterly ...

Medtronic plc revealed new data which showed that its Symplicity Spyral renal denervation (RDN) system significantly reduced blood pressure (BP) in a diverse patient population. Office systolic BP ...

The publication this spring in The Lancet Respiratory Medicine of new data with Amgen Inc. and Astrazeneca plc’s Tezspire (tezepelumab) fed hopes in severe asthma, where a handful of developers are ...

Colorectal cancer (CRC) remains difficult to treat, particularly after resistance to targeted therapies and immunotherapy ...

Researchers are taking new steps to improve CAR T-cell therapies by better understanding their behavior and engineering them to overcome some of their limitations, from treatment failure and T-cell ...

Prostate-specific membrane antigen (PSMA) is overexpressed in primary and metastatic prostate cancer, including metastatic lesions in lymph nodes and bone, compared with normal prostate tissues. ADC ...

At Bioplus Interphex Korea 2026 in Seoul, panelists noted that “transformative” technological architecture, including large ...

Blackstone Life Sciences entered into a $455 million deal with Boston Scientific Corp. to co-fund the development of Vitalyst ...

Fresenius SE & Co. KGaA has secured exclusive options to develop up to 37 biosimilars with Wuxi Biologics Co. Ltd. in a ...